Phio Pharmaceuticals Corp. Net Income Loss

• Phio Pharmaceuticals Corp. showed a decrease of -21.7% in Net Income Loss from 2024 to 2025.
• This data is from Phio Pharmaceuticals Corp.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
• XBRL data for this metric is available from 2003 to 2025 (23 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 23 years of available data (2003 to 2025), Phio Pharmaceuticals Corp.'s Net Income Loss has declined by 9,673.0%.
• Historical annual values: Fiscal year 2025: -$8.70 million | Fiscal year 2024: -$7.15 million | Fiscal year 2023: -$10.83 million | Fiscal year 2022: -$11.48 million | Fiscal year 2021: -$13.29 million | Fiscal year 2020: -$8.79 million | Fiscal year 2019: -$8.91 million | Fiscal year 2018: -$7.36 million | Fiscal year 2017: -$12.45 million | Fiscal year 2016: -$8.99 million | Fiscal year 2015: -$10.22 million | Fiscal year 2014: -$8.80 million | Fiscal year 2013: -$20.93 million | Fiscal year 2012: -$12.88 million | Fiscal year 2011: -$2.54 million | Fiscal year 2010: -$11.99 million | Fiscal year 2009: -$18.39 million | Fiscal year 2008: -$14.37 million | Fiscal year 2007: -$10.99 million | Fiscal year 2006: -$2.41 million | Fiscal year 2005: -$2.21 million | Fiscal year 2004: -$3.27 million | Fiscal year 2003: -$89.0 thousand.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026